Literature DB >> 3783598

Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine.

L Y Leung, T A Baillie.   

Abstract

(Z)-6-Hydroxynorketamine (3), a secondary metabolite of the dissociative anesthetic agent ketamine (1), was synthesized, and its central nervous system (CNS) properties were compared to those of the parent drug and the primary metabolite, norketamine (2). Administration of compounds 1 and 2 to rats (40 mg/kg iv) produced general anesthesia and also led to marked increases in spontaneous locomotor activity during the postanesthetic recovery phase. These effects were of significantly longer duration with 1 than with 2. In contrast, the same dose of 3 produced neither general anesthesia nor CNS excitation, despite the fact that 3 entered brain tissue readily from the systemic circulation. It is concluded that the CNS effects of 1 are attenuated by metabolism to 2 and are abolished by subsequent hydroxylation to produce 3. Moreover, the results suggest that the desirable anesthetic properties of 1 and related arylcyclohexylamines may be inseparable from their ability to produce adverse postanesthetic emergence reactions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3783598     DOI: 10.1021/jm00161a043

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  41 in total

1.  Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing.

Authors:  Samuel Fanta; Mari Kinnunen; Janne T Backman; Eija Kalso
Journal:  Eur J Clin Pharmacol       Date:  2015-03-01       Impact factor: 2.953

2.  A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome.

Authors:  Ruin Moaddel; Swarajya Lakshmi Vattem Venkata; Mary J Tanga; James E Bupp; Carol E Green; Lalitha Iyer; Anna Furimsky; Michael E Goldberg; Marc C Torjman; Irving W Wainer
Journal:  Talanta       Date:  2010-08-13       Impact factor: 6.057

3.  Hydroxynorketamine Blocks N-Methyl-d-Aspartate Receptor Currents by Binding to Closed Receptors.

Authors:  Jamie A Abbott; Gabriela K Popescu
Journal:  Mol Pharmacol       Date:  2020-06-29       Impact factor: 4.436

Review 4.  Ketamine for chronic pain: risks and benefits.

Authors:  Marieke Niesters; Christian Martini; Albert Dahan
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

5.  What is hydroxynorketamine and what can it bring to neurotherapeutics?

Authors:  Nagendra S Singh; Carlos A Zarate; Ruin Moaddel; Michel Bernier; Irving W Wainer
Journal:  Expert Rev Neurother       Date:  2014-11       Impact factor: 4.618

6.  Are basal D-serine plasma levels a predictive biomarker for the rapid antidepressant effects of ketamine and ketamine metabolites?

Authors:  Irving W Wainer
Journal:  Psychopharmacology (Berl)       Date:  2014-09-11       Impact factor: 4.530

7.  The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brain-stimulation reward.

Authors:  L J Herberg; I C Rose
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine.

Authors:  Jaclyn N Highland; Patrick J Morris; Panos Zanos; Jacqueline Lovett; Soumita Ghosh; Amy Q Wang; Carlos A Zarate; Craig J Thomas; Ruin Moaddel; Todd D Gould
Journal:  J Psychopharmacol       Date:  2018-11-29       Impact factor: 4.153

9.  (R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function.

Authors:  Rajib K Paul; Nagendra S Singh; Mohammed Khadeer; Ruin Moaddel; Mitesh Sanghvi; Carol E Green; Kathleen O'Loughlin; Marc C Torjman; Michel Bernier; Irving W Wainer
Journal:  Anesthesiology       Date:  2014-07       Impact factor: 7.892

10.  Comparison of morphine and morphine with ketamine for postoperative analgesia.

Authors:  K B Javery; T W Ussery; H G Steger; G W Colclough
Journal:  Can J Anaesth       Date:  1996-03       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.